

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE
STATEMENT

Patent Application
Docket No. ARO-102
Serial No. 09/297,649

January 11, 2005

David R. Saliwanchik

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	:	1743
Applicant(s)	:	Jack L. Aronowitz
Serial No.	:	09/297,649
Filed	:	May 4, 1999
Conf. No.	:	1097
For	:	Noninvasive Transdermal Systems for Detecting Analytes

RECEIVED

JAN 27 2005

TECHNOLOGY CENTER R3700

RECEIVED

JAN 24 2005

TC 1700

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the first page of the cited patent documents and a copy of the cited abstract are enclosed.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate

marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.


Respectfully submitted,



David R. Saliwanchik
Patent Attorney
Registration No. 31,794
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRS/lj

Attachments: Form PTO/SB/08
Copies of the first page of the cited patent documents
Copy of the abstract of the cited literature document



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1			Complete if Known	
			Application Number	09/297,649
			Filing Date	May 4, 1999
			First Named Inventor	Jack L. Aronowitz
			Group Art Unit	1743
			Examiner Name	
			Attorney Docket Number	ARO-102

RECEIVED
JAN 27 2005
TECHNOLOGY CENTER

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	4,595,011		Phillips	06-17-1986	
	U2	4,706,676		Peck	11-17-1987	
	U3	4,960,467		Peck	10-02-1990	
	U4	5,462,064		D'Angelo <i>et al.</i>	10-31-1995	
	U5	5,465,713		Schoendorfer	11-14-1995	
	U6	6,503,198		Aronowtiz <i>et al.</i>	01-07-2003	
	U7					

RECEIVED
JAN 24 2005
TC 1700

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1		WO 97/02811		Cygnus Incorporated	01-30-1997		
	F2							
	F3							

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	Biological Abstracts, vol. 90, Philadelphia, PA, US; abstract no. 20245, see abstract & MURPHY <i>et al.</i> , Transcutaneous Theophylline Collection in Preterm Infants, <i>Clinical Pharmacology and Therapy</i> (1990), vol. 47, no. 4, pages 427-434 (Abstract Only).	
	R2		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.